tella, Inc. engages in research and development of dendritic cell (DC) vaccine therapy. It operates through the following business segments: Cell Medicine, Medical Support, and Pharmaceuticals. The Cell Medicine segment involves in the provision of cancer treatment technologies and chiefly the dendritic cell vaccine therapy. The Medical Support segment deals with the operation of cell processing facilities by contract, sales of cell processing devices and also provides the genetic diagnosis support business. The Pharmaceuticals segment handles the development activities for the purpose of receiving pharmaceutical approval of the DC vaccine as a regenerative medicine product for treating cancer. It also provides the consultation on the establishment and maintenance of cell processing centers (CPC); introduction of management systems for cell cultivation; lease of SOP (standard operating procedure) and regular checks on manufacturing operation management and training of cell cultivation technicians. The company was founded by Yuichiro Yazaki on June 24, 2004 and is headquartered in Tokyo, Japan.